Ceribell has received FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection and monitoring solution. This first-in-class device leverages the company’s existing point-of-care EEG hardware combined with an AI-driven algorithm to detect LVO strokes in hospitalized patients. The designation follows Ceribell’s recent FDA 510(k) clearances for its Clarity® neonatal seizure detection algorithm (November 2025) and its delirium screening solution (December 2025), underscoring Ceribell’s expanding regulatory momentum in acute-care brain monitoring.

Approximately 800,000 strokes occur annually in the U.S., with up to 17% classified as in-hospital onset. LVO strokes account for nearly 62% of post-stroke dependence and 96% of stroke-related mortalities, highlighting the urgent need for faster detection. Scientific studies indicate that in-hospital strokes face an average delay of several hours before identification, leading to three times higher mortality rates and half the likelihood of discharge to home compared to community-onset strokes. Every minute saved in LVO detection translates into a week of disability-free life, presenting a compelling value proposition for hospitals aiming to improve outcomes and reduce long-term care costs.

The Breakthrough Device status not only validates Ceribell’s technology but also positions the company to accelerate clinical adoption and reimbursement discussions. Ceribell plans prospective, multi-center validation studies to support commercial launch, targeting the 15,000 U.S. hospitals without continuous EEG capability. By converting just 10% of these facilities, Ceribell could install over 1,500 LVO monitors in the next three years. Management projects that commercialization of the LVO solution could increase annual revenue by 30–40%, driven by device sales and recurring algorithm licensing fees.

Ceribell’s point-of-care EEG platform is differentiated by its rapid deployment (under two minutes) and continuous monitoring capability. The company’s next steps include securing Centers for Medicare & Medicaid Services (CMS) coverage and finalizing pivotal trial protocols with leading stroke centers. With an estimated global addressable market of $2.5 billion for in-hospital stroke monitoring devices, Ceribell’s LVO solution could extend its leadership in acute neuromonitoring and create cross-sell opportunities for its existing seizure and delirium products.